Skip to main content Accessibility help
Hostname: page-component-684899dbb8-plzwj Total loading time: 7.469 Render date: 2022-05-23T09:12:05.566Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "useNewApi": true }

Book contents

25 - Management of cancer of the ovary

Published online by Cambridge University Press:  05 November 2015

Rachel Jones
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff, UK
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access



Ovarian cancer is the fifth most common cancer in women and the second most common gynaecological cancer, but the most common cause of death from gynaecological malignancy in the Western world. Epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer share similar characteristics and behaviour and are treated in the same way. Ovarian cancer has been named a ‘silent killer’ because of its lack of symptoms during early stages. Around 90% of ovarian cancers arise from the epithelium. Two-thirds of patients present with stage III or IV disease, with increasing abdominal symptoms including ascites. Treatment typically depends on a combination of surgery and chemotherapy. In recent years there has been interest in the role of biological treatments, particularly the angiogenesis inhibitor, bevacizumab. Over the past 40 years there has been a modest increase in the survival from ovarian cancer in the UK, attributable primarily to the use of platinum-based chemotherapy, and around 40% of patients are expected to survive for 5 years or more.

Types of tumour affecting the ovary

The WHO classification of tumours of the ovary defines broad categories of ovarian tumours (WHO classification, 2003):

  1. • surface epithelial–stromal tumours;

  2. • sex cord–stromal tumours;

  3. • germ cell tumours;

  4. • tumours of the rete ovarii;

  5. • miscellaneous tumours;

  6. • lymphomas and haematopoietic tumours;

  7. • secondary tumours.

Surface epithelial–stromal tumours are classified as benign, borderline or malignant. The subtypes are serous, mucinous, endometrioid, malignant mixed müllerian tumour (carcinosarcoma), clear cell, transitional cell, squamous cell, mixed and undifferentiated or unclassified.

Sex cord–stromal tumours are classified as granulosa tumours (including granulosa cell tumours and theca-fibroma tumours), sertoli cell tumours, sex-cord tumours of mixed or unclassified cell types, gynandroblastoma and steroid cell tumours.

Germ cell tumours are classified as primitive germ cell tumours (including dysgerminoma, yolk sac tumour and embryonal carcinoma), biphasic or triphasic teratomas (including immature teratoma and mature teratoma), and monodermal teratoma (composed of a single type of tissue and includes struma ovarii, which is composed of thyroid cells).

Incidence and epidemiology

The annual incidence of ovarian cancer in the UK is 17 per 100,000 women, ranging from 14 per 100,000 in Northern Ireland to 20 per 100,000 in Wales. Approximately 7000 cases are reported per year in the UK.

Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Aghajanian, C., Blank, S., Goff, B., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer. J. Clin. Oncol., 30, 2039–2045.CrossRefGoogle ScholarPubMed
Anonymous, . (1991). Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br. Med. J., 303, 884–893.Google Scholar
Anonymous, . (1998). ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet, 352, 1571–1576.Google Scholar
Antoniou, A., Pharoah, P. D., Narod, S., et al. (2003). Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet., 72, 1117–1130.CrossRefGoogle ScholarPubMed
Ayhan, A., Gultekin, M., Dursun, P., et al. (2008). Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance?Gynecol. Oncol., 108, 428–432.CrossRefGoogle ScholarPubMed
Bookman, M., Brady, M., McGuire, W., et al. (2009). Evaluation of new-platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol., 27, 1419–1425.CrossRefGoogle ScholarPubMed
Bower, M., Fife, K., Holden, L., et al. (1996). Chemotherapy for ovarian germ cell tumours. Eur. J. Cancer, 32A, 593–597.Google ScholarPubMed
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., et al. (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol., 20, 1248–1259.CrossRefGoogle ScholarPubMed
Burger, R., Brady, M., Brookman, M., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New Engl. J. Med., 365, 2473–2483.CrossRefGoogle ScholarPubMed
Callahan, M. J., Crum, C. P., Medeiros, F., et al. (2007). Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol., 25, 3985–3990.CrossRefGoogle ScholarPubMed
Cantu, M., Buda, A., Parma, G., et al. (2002). Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J. Clin. Oncol., 20, 1232–1237.CrossRefGoogle ScholarPubMed
Chan, J., Brady, M., Penson, R., et al. (2013). Phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT0116712). Int. J. Gynecol. Cancer, 23 (8 suppl 1), 9–10.
Ferrandina, G., Ludovisi, M., Lorusso, D., et al. (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J. Clin. Oncol., 26, 890–896.CrossRefGoogle ScholarPubMed
Gordon, A. N., Tonda, M., Sun, S., et al. (2004). Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol. Oncol., 95, 1–8.CrossRefGoogle Scholar
Hanna, L. and Adams, M. (2006). Prevention of ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol., 20, 339–362.CrossRefGoogle ScholarPubMed
Herzog, T. J. (2002). Update on the role of topotecan in the treatment of recurrent ovarian cancer. Oncologist, 7(Suppl. 5), 3–10.CrossRefGoogle ScholarPubMed
ICON Group. (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON 3 randomised trial. Lancet, 360, 505–515.
Kaern, J., Baekelandt, M. and Trope, C. (2002). A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur. J. Gynaecol. Oncol., 23, 383–389.Google ScholarPubMed
Katsumata, N., Yasuda, M., Isonishi, S., et al. (2012). Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, fallopian rube or primary peritoneal cancer: JGOG 3016 trial. J. Clin. Oncol., 15 (Suppl.), abstract 5003.Google Scholar
Kehoe, S., Hook, J., Nankivell, N., et al. (2013). Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J. Clin Oncol., 31(Suppl.), abstract 5500.Google Scholar
Kindelberger, D., Lee, Y., Miron, A., et al. (2007). Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol., 32, 161–169.Google Scholar
Kurman, R. and Shih, leM. (2010). The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol., 34, 433–443.CrossRef
Kyrgiou, M., Salanti, G., Pavlidis, N., et al. (2006). Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J. Natl Cancer Inst., 98, 1655–1663.CrossRefGoogle ScholarPubMed
Ledermann, J., Harter, P., Gourley, G., et al. (2014). Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol., 15, 852–861.CrossRef
Liu, G., Yang, D., Sun, Y., et al. (2012). Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer. Pharmacogenomics, 13, 1523–1535.CrossRef
Longacre, T. A., McKenney, J. K., Tazelaar, H. D., et al. (2005). Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or = 5-year) follow-up. Am. J. Surg. Pathol., 29, 707–723.CrossRefGoogle ScholarPubMed
Lu, K. H., Dinh, M., Kohlmann, W., et al. (2005). Gynecologic cancer as a ‘sentinal cancer’ for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet. Gynecol., 105, 569–574.CrossRefGoogle Scholar
Markman, M., Blessing, J., Rubin, S., et al. (2006). Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol. Oncol., 101, 436–440.CrossRefGoogle Scholar
McGuire, W. P., Hoskins, W. J., Brady, M. F., et al. (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med., 334, 1–6.CrossRefGoogle ScholarPubMed
Meeuwissen, P. A., Seynaeve, C., Brekelmans, C. T., et al. (2005). Outcome of surveillance and prophylactic salpingooophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol. Oncol., 97, 476–482.CrossRefGoogle Scholar
Menon, U., Gentry-Maharaj, A., Hallett, R., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol., 10, 327–340.CrossRefGoogle Scholar
Moran, B. J. and Cecil, T. D. (2003). The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg. Oncol. Clin. N. Am., 12, 585–603.CrossRefGoogle ScholarPubMed
Muggia, F. and Hamilton, A. (2001). Phase II data on Caelyx® in ovarian cancer. Eur. J. Cancer, 37 (Suppl. 9), S15–18.CrossRefGoogle Scholar
Muggia, F. M., Braly, P. S., Brady, M. F., et al. (2000). Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 18, 106–115.CrossRefGoogle ScholarPubMed
Mutch, D., Orlando, M., Goss, T., et al. (2007). Randomized phase III trial of Gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol., 25, 2811–2818.CrossRefGoogle ScholarPubMed
NICE. (2003). Technology Appraisal Guidance – No. 55. Guidance of the Use of Paclitaxel in the Treatment of Ovarian Cancer. London: National Institute for Clinical Excellence.
NICE. (2005). Technology Appraisal Guidance – No. 91. Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride and Topotecan for Second-line or Subsequent Treatment of Advanced Ovarian Cancer. Review of Technology Appraisal Guidance 28, 45 and 55. London: National Institute for Clinical Excellence.
NICE. (2011). Clinical Guideline 122; Ovarian Cancer – The Recognition and Initial Management of Ovarian Cancer.London: National Institute for Clinical Excellence.
NICE. (2013). Technology Appraisal Guidance – TA 284. Bevacizumab in Combination with Paclitaxel and Carboplatin for First-line Treatment of Advanced Ovarian Cancer. London: National Institute for Clinical Excellence.
Oza, A. M., Cook, A. D., Pfisterer, J., et al., (2015). Standard chemothrapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol., 16, 928–936.CrossRef
Parmar, M. K., Ledermann, J. A., Colombo, N., et al. (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet, 361, 2099–2106.Google ScholarPubMed
Pfisterer, J., Plante, M., Vergote, I., et al. (2006). Gemcitabine and carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG.J. Clin. Oncol., 24, 4699–4707.CrossRefGoogle ScholarPubMed
Piccart, M. J., Bertelsen, K., James, K., et al. (2000a). Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst., 92, 699–708.Google ScholarPubMed
Piccart, M. J., Green, J., Lacave, L., et al. (2000b). Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer gynecology group. J. Clin. Oncol., 18, 1193–1202.CrossRefGoogle ScholarPubMed
Pignata, S., Scambia, G., Katsaros, D., et al. (2014). Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO): a randomized, multicentre, open-label phase 3 trial. Lancet Oncol., 15, 396–405.CrossRef
Poveda, A., Vergote, I., Tjulandin, S., et al. (2011). Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer in the partially-platinum sensitive sub-population of OVA-301 phase III randomised trial. Ann. Oncol., 22, 39–48.CrossRefGoogle Scholar
Prat, J. (2013). Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. ScholarPubMed
Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol., 32, 1302–1308.CrossRef
Risch, H. A., McLaughlin, J. R., Cole, D. E., et al. (2001). Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet., 68, 700–710.CrossRefGoogle Scholar
Rose, P., Blessing, J., Mayer, A., et al. (1998). Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol., 16, 405–410.CrossRefGoogle ScholarPubMed
Rosenthal, A., Fraser, L., Manchanda, R., et al. (2013). Results of annual screening in phase I of the United Kingdom Familial Ovarian Cancer Screening study highlight the need for strict adherence to screening schedule. J. Clin.Oncol., 31, 49–57.CrossRefGoogle ScholarPubMed
Runowicz, C. (2006). Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery?Nat. Clin. Pract. Oncol., 3, 416–417.CrossRefGoogle ScholarPubMed
Rustin, G., van der Burg, M., Griffin, C., et al. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC 0V05/EORTC 55955): a randomised trial. Lancet, 376, 1155–1163.CrossRefGoogle ScholarPubMed
Sato, N., Tsunoda, H., Nishida, M., et al. (2000). Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res., 60, 7052–7056.
SIGN. (2003). Guideline 75. Epithelial Ovarian Cancer. Edinburgh: Scottish Intercollegiate Guidelines Network.
Struewing, J. P., Hartge, P., Wacholder, S., et al. (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N. Engl. J. Med., 336, 1401–1408.CrossRefGoogle ScholarPubMed
ten Bokkel Huinink, W., Lane, S. and Ross, G. (2004). Long-term survival in a phase III randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann. Oncol., 15, 100–103.CrossRefGoogle Scholar
Thigpen, J., Blessing, J., Ball, H., et al. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology group study. J. Clin. Oncol. 12, 1748–1753.CrossRefGoogle ScholarPubMed
Trimble, E., Adams, J., Vena, D., et al. (1993). Paclitaxel for platinum-refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center. J. Clin.Oncol., 11, 2405–2410.CrossRefGoogle ScholarPubMed
Trimbos, J. B., Parmar, M., Vergote, I., et al. (2003). International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl Cancer. Inst., 95, 105–112.CrossRefGoogle ScholarPubMed
Vergote, I., Tropé, C. G., Amant, F., et al. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med., 363, 943–953.CrossRefGoogle ScholarPubMed
Wagner, U., Marth, C., Largillier, R., et al. (2012). Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer, 107, 588–591.CrossRefGoogle ScholarPubMed
Winter, E., Maxwell, L., Tian, C., et al. (2008). Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol., 26, 83–89.CrossRefGoogle ScholarPubMed
WHO Classification. (2003). In World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, ed. Tavassoli, A. and Devilee, P.. Lyon: IARC Press, Chapter 4.

Save book to Kindle

To save this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the or variations. ‘’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats